Ȩ > Publication > ±¹ Á¦

ÀÛ¼ºÀÚ :      ÀÛ¼ºÀÏ :     2009-02-25 (19:34:15)
À̸ÞÀÏ :      Á¶È¸¼ö :     17741
ȨÆäÀÌÁö :      ¾ÆÀÌÇÇ :     ***.***.***.***
±ÛÁ¦¸ñ :     E2F decoy oligodeoxynucleotides on neointimal hyperplasia in canine vein graft.
 
 Transplant Proc. 2005 Jan-Feb;37(1):77-9.

E2F decoy oligodeoxynucleotides on neointimal hyperplasia in canine vein graft.

Cho WH, Lee SO, Kim HT, Ahn JD, Lee IK.

Department of Surgery, Institute for Medical Science, Keimyung University, Daegu, Korea. wh51cho@dsmc.or.kr

Double-stranded DNA with high affinity to E2F as a decoy cis-element blocks the activation of genes mediating the cell cycle, resulting in effective suppression of the smooth muscle cell proliferation that causes intimal hyperplasia. To evaluate the effect of the E2F decoy to suppress neointimal hyperplasia autogenous venous bypass grafts were performed in dogs after incubation with heparin (group 1), with E2F decoy oligodeoxynucleotides (ODN) (groups 2 and 3), or with a random ODN (group 4) using a Japan-liposomeal method based on a hemagglutinating virus. The intimal and medial cross-sectional surface area of the anastomotic site was measured at 4 months after bypass surgery in groups 1, 3, and 4 by computerized planimetry and at 4 weeks in group 2 to compare the intimal/medial (I/M) area ratios. Autogenous vein grafts treated with E2F decoy showed a significant reduction in I/M area ratio (0.26 +/- 0.11) compared with the heparin-treated control group (1.49 +/- 0.29) or the mismatched ODN-treated group (1.61 +/- 0.28; P = .000). There was no difference in the I/M area ratio according to experimental periods (groups 2 vs 3: 0.26 +/- 0.11 vs 0.37 +/- 0.32; P = .446) or the anastomotic sites (proximal vs distal; P = .934). In conclusion, an E2F decoy can suppress neointimal hyperplasia in autogenous vein grafts, which may prolong patency by reducing graft stenosis.

PMID: 15808553 [PubMed - indexed for MEDLINE]

 
 
 
name :
password :
  comment :
 
 
ÀÌÀü±Û ¸ñ·Ï »õ±Û¾²±â ÀÀ´ä±Û¾²±â ±Û¼öÁ¤Çϱ⠱ÛÁö¿ì±â ´ÙÀ½±Û



76 A transcriptional factor decoy against AP-1 suppresses TGF-beta1-induced type I collagen gene expres  2009.02.2617643
75 Circular dumbbell AP-1 and E2F decoy oligodeoxynucleotide based antiproliferative gene therapy  2009.02.2611889
E2F decoy oligodeoxynucleotides on neointimal hyperplasia in canine vein graft.  2009.02.2517741
73 Inhibitory effects of novel E2F decoy oligodeoxynucleotides on mesangial cell proliferation by coexp  2009.02.2522452
72 E2F decoy oligodeoxynucleotides effectively inhibit growth of human tumor cells.  2009.02.2518238
71 Advantages of the circular dumbbell decoy in gene therapy and studies of gene regulation.  2009.02.2512565
70 Dexamethasone regulates AP-1 to repress TNF-alpha induced MCP-1 production in human glomerular endot  2009.02.2524712
69 Relationship between serum adiponectin and leptin concentrations and body fat distribution.  2009.02.2515763
68 Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats.  2009.02.2537567
67 Inhibition of ATP-sensitive K+ channels by taurine through a benzamido-binding site on sulfonylurea  2009.02.2520593
66 Tumor necrosis factor-alpha induces fractalkine expression preferentially in arterial endothelial ce  2009.02.2517297
65 Sp1-decoy oligodeoxynucleotide inhibits high glucose-induced mesangial cell proliferation.  2009.02.2515711
64 Transcription factor decoy for AP-1 reduces mesangial cell proliferation and extracellular matrix pr  2009.02.2517077
63 SREBP-1c mediates the insulin-dependent hepatic glucokinase expression.  2009.02.2517715
62 Differential regulation of human and mouse orphan nuclear receptor small heterodimer partner promote  2009.02.2518787
61 Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated prot  2009.02.2514845
60 Effect of antisense TGF-beta1 oligodeoxynucleotides in streptozotocin- induced diabetic rat kidney.  2009.02.2514936
59 Taurine increases glucose sensitivity of UCP2-overexpressing {beta}-cells by ameliorating mitochondr  2009.02.2514905
58 Analysis of proteome and transcriptome of tumor necrosis factor alpha stimulated vascular smooth mus  2009.02.2517501
57 Prevention and treatment of macroangiopathy: focusing on oxidative stress.  2009.02.2517720
[1] 2 [3][4][5]
¸ñ·Ï »õ±Û¾²±â